Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Payables: 2016-2025

Historic Payables for Ascendis Pharma A (ASND) over the last 4 years, with Sep 2025 value amounting to $498.3 million.

  • Ascendis Pharma A's Payables rose 7.50% to $498.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 billion, marking a year-over-year increase of 5.53%. This contributed to the annual value of $600.3 million for FY2024, which is 11.21% up from last year.
  • As of Q3 2025, Ascendis Pharma A's Payables stood at $498.3 million, which was up 5.29% from $473.2 million recorded in Q2 2025.
  • In the past 5 years, Ascendis Pharma A's Payables ranged from a high of $598.2 million in Q3 2023 and a low of $76.0 million during Q4 2021.
  • For the 3-year period, Ascendis Pharma A's Payables averaged around $509.3 million, with its median value being $498.3 million (2025).
  • Per our database at Business Quant, Ascendis Pharma A's Payables spiked by 369.59% in 2023 and then fell by 22.51% in 2024.
  • Quarterly analysis of 5 years shows Ascendis Pharma A's Payables stood at $76.0 million in 2021, then soared by 51.29% to $114.9 million in 2022, then surged by 369.59% to $539.8 million in 2023, then rose by 9.80% to $592.6 million in 2024, then increased by 7.50% to $498.3 million in 2025.
  • Its Payables stands at $498.3 million for Q3 2025, versus $473.2 million for Q2 2025 and $472.9 million for Q1 2025.